<DOC>
	<DOC>NCT01097018</DOC>
	<brief_summary>The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.</brief_summary>
	<brief_title>Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients must have failed available therapy for the treatment of advanced colorectal cancer, including fluoropyrimidine, irinotecan, oxaliplatin, bevacizumab and for Kras wildtype (WT) patients, antiEGFR antibody (cetuximab or panitumumab) containing therapies. For oxaliplatinbased therapy, failure of therapy will also include patients who had oxaliplatin discontinued secondary to toxicity. No prior exposure to capecitabine in the metastatic colorectal cancer setting, except limitedcourse radiosensitizing capecitabine Patients must have at least one measurable lesion by RECIST criteria Patients with known dipyrimidine dehydrogenase (DPD) deficiency or prior severe reaction to 5FU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>